Schroder Investment Management Group Ultragenyx Pharmaceutical Inc. Call Options Transaction History
Schroder Investment Management Group
- $112 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RARE
# of Institutions
361Shares Held
86.6MCall Options Held
3.64MPut Options Held
2.24M-
Vanguard Group Inc Valley Forge, PA10.2MShares$353 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$194 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA3.94MShares$136 Million0.43% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.89MShares$99.9 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY2.77MShares$95.9 Million1.02% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $2.42B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...